Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Protection from bb rat diabetes by the platelet-activating factor inhibitor BN50730

Jobe, Lance W. ; Ubungen, Roel ; Goodner, Charles J. ; Baskin, Denis G. ; Braquet, Pierre and Lernmark, Åke LU orcid (1993) In Autoimmunity 16(4). p.259-266
Abstract

The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p <0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p <0.01) and high (p <0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p <0.001). Serum insulin in... (More)

The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p <0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p <0.01) and high (p <0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p <0.001). Serum insulin in BN50730-protected compared to unprotected rats was 114±49 and 32±22 (p <0.001) in the low, and 91 ± 4 6 and 21 ± 15 (p <0.001) μU/ml in the high dose group, respectively. Increased serum insulin correlated with preserved islet β cells and decreased insulitis. Treatment did not affect thyroiditis. Thus, platelet-activating factor may be involved in insulitis pathogenesis and platelet-activating factor inhibitors may decrease autoimmune β cell destruction.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Biobreeding (BB) rats, IDDM (insulin-dependent diabetes mellitus), Insulitis, PAF
in
Autoimmunity
volume
16
issue
4
pages
259 - 266
publisher
Taylor & Francis
external identifiers
  • scopus:0027889129
  • pmid:8025205
ISSN
0891-6934
DOI
10.3109/08916939309014644
language
English
LU publication?
no
id
c2ad08a7-e818-4ee6-b386-3baf70ec5704
date added to LUP
2019-09-11 09:24:16
date last changed
2024-03-13 08:17:11
@article{c2ad08a7-e818-4ee6-b386-3baf70ec5704,
  abstract     = {{<p>The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p &lt;0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed onset to 87 ± 15 days in the low and 93 ± 12.days (p &lt;0.01) in high dose rats. The relative degree of insulitis was reduced in both low (p &lt;0.01) and high (p &lt;0.05) dose treated groups. Serum insulin in young prediabetic controls decreased from 84±34 μU/ml to 38 ± 20 in the 22 rats developing diabetes (p &lt;0.001). Serum insulin in BN50730-protected compared to unprotected rats was 114±49 and 32±22 (p &lt;0.001) in the low, and 91 ± 4 6 and 21 ± 15 (p &lt;0.001) μU/ml in the high dose group, respectively. Increased serum insulin correlated with preserved islet β cells and decreased insulitis. Treatment did not affect thyroiditis. Thus, platelet-activating factor may be involved in insulitis pathogenesis and platelet-activating factor inhibitors may decrease autoimmune β cell destruction.</p>}},
  author       = {{Jobe, Lance W. and Ubungen, Roel and Goodner, Charles J. and Baskin, Denis G. and Braquet, Pierre and Lernmark, Åke}},
  issn         = {{0891-6934}},
  keywords     = {{Biobreeding (BB) rats; IDDM (insulin-dependent diabetes mellitus); Insulitis; PAF}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{4}},
  pages        = {{259--266}},
  publisher    = {{Taylor & Francis}},
  series       = {{Autoimmunity}},
  title        = {{Protection from bb rat diabetes by the platelet-activating factor inhibitor BN50730}},
  url          = {{http://dx.doi.org/10.3109/08916939309014644}},
  doi          = {{10.3109/08916939309014644}},
  volume       = {{16}},
  year         = {{1993}},
}